Navigation Links
Genomic Health Presents Multiple International Studies Demonstrating Worldwide Value of Oncotype DX® Breast Cancer Test
Date:3/17/2011

s product pipeline ; the company's belief that its research and pipeline reflect its ongoing commitment to develop and deliver tools to individualize cancer treatment decisions; the belief that study data may warrant or result in additional clinical studies or impact treatment decisions; and the applicability of clinical study results to actual outcomes. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and uncertainties associated with the regulation of the company's tests; the impact of competition,  the results of clinical studies; the results of cost effectiveness  studies;  the applicability of clinical study results to actual outcomes; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Annual Report  on Form 10-K  for the year  ended December 31, 2010 . These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.


'/>"/>
SOURCE Genomic Health, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Reminder Webcast Alert: Transgenomic to Hold Fourth Quarter Financial Results Conference Call on March 11, 2011
2. Transgenomic to Hold Fourth Quarter Financial Results Conference Call on March 11, 2011
3. Everist Genomics Laboratory Receives Approval From U.S. Regulatory Authorities For High Complexity Clinical Testing
4. Researchers use genomics to investigate TB outbreak
5. Transgenomic to Present at the Lippert/Heilshorn Life Sciences & Medtech Virtual Conference on February 17
6. Genomic Health Announces Results from Biomarker Discovery Program Utilizing Next-Generation Sequencing to Compare Normal and Tumor Breast Tissue
7. Sigma Life Science Collaborates with Cofactor Genomics to Develop Publically Available Rat Genome Database
8. Four Community Hospitals Join DNA Directs Genomic Medicine Network
9. Genomic Health Announces Multiple Colon Cancer Studies at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium
10. Everist Genomics Announces External Validation of OncoDefender™-CRC Test for Predicting Recurrence Risk for Stage I and II Colorectal Cancer Patients
11. BioInformatics, LLC New Market Report - Genomics Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... and PARIS , July ... Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that ... Drug Administration (FDA) rare pediatric disease priority review voucher ... for alirocumab.  The priority review voucher entitles the holder ... for an expedited 6-month review from the filing date ...
(Date:7/30/2014)... , July 30, 2014  Decision Resources ... and medical directors in the United ... of biosimilar market penetration will be the level ... (MCOs) and the expected lower cost to patients. ... biosimilars that meet their pricing expectations in order ...
(Date:7/30/2014)... , July 30, 2014  The Chicago Bears ... American Academy of Dermatology (Academy) in an effort to ... Chicago Bears will host free SPOT me™ skin cancer ... 2 at Soldier Field. SPOT me™ is an ... about the dangers and risks of skin cancer, and ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 While ... in health services research for a relatively long ... in interest regarding the use of these ‘big ... conditions. , By combining today’s powerful computer technology ... digital era, ‘big data’ holds significant promise for ...
Breaking Biology Technology:Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 2Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 3Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 4Leveraging ‘Big Data’ - Methodological Considerations in Health Services Research, New Webinar Hosted by Xtalks 2
... Morria Biopharmaceuticals,Plc, a biopharmaceutical company focused on ... ICH compliant Phase II equivalent,multi-center study of MRX-4 ... given as an intranasal spray formulation., The ... allergic,rhinitis patients outside of the local allergy season. ...
... new apoA1 measurement and apoB:apoA1 ratio to its, comprehensive cholesterol ... ... heart disease, BIRMINGHAM, Ala., Nov. 6 Atherotech, ... Test in booth No. 2918 at the American Heart Association,Scientific Sessions ...
... 6 Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: NTII ) ... 30, 2008, the first quarter of the,company,s fiscal year ... September 30, 2008 was $3.6 million, compared to $3.9 ... expenses were $6.8 million,for the first quarter of fiscal ...
Cached Biology Technology:Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients 2Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients 3Atherotech to Exhibit VAP(R) Cholesterol Test at American Heart Association Scientific Sessions 2008 2Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results 2Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results 3Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results 4Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results 5
(Date:7/30/2014)... reversible epigenetic processes to regulate its genes, and adapt ... picture of the genome regulation taking place in the ... Genome Biology and illustrates how the truffle deals ... The authors say this may shed light on how ... truffles (Tuber melanosporum), also known as Prigord truffles, have ...
(Date:7/30/2014)... the potential effects of climate change on the ... the wrong factors, according to a new paper ... Society, University of Queensland, and other organizations. The ... is missing the point when it comes to ... climate change scientists focus on the "direct" threats ...
(Date:7/30/2014)... a joint venture between The University of Texas at ... Science Center at San Antonio, has selected the winners ... Boice from UTSA and Lei Huang from the Health ... "Novel engineered ferritins for tracking and protecting neural stem ... is focused on finding a treatment for stroke through ...
Breaking Biology News(10 mins):How black truffles deal with the jumpers in their genome 2Conservation scientists asking wrong questions on climate change impacts on wildlife 2
... The Missouri Botanical Garden in St. Louis, Mo. ... of China,s botanical institutions in an effort to promote ... beneficial agreement between the Missouri Botanical Garden and the ... of Botany calls for the exchange of herbarium specimens, ...
... the University of Georgia have developed a "super strain" ... pine -- one of the most common species of ... help biofuels replace gasoline as a transportation fuel. ... such as pine, but it is a notoriously difficult ...
... GAITHERSBERG, MD, Nov. 18 As clinical studies ... promote general gastrointestinal health, a growing U.S. market1 for ... alike are recognizing the value of these beneficial microorganisms. ... directing patients to the best probiotic for their individual ...
Cached Biology News:Missouri Botanical Garden signs exchange agreement with 3 botanical institutions in China 2UGA researchers develop 'super' yeast that turns pine into ethanol 2As probiotics use grows for gut health, VSL#3 has designations for specific GI issues 2As probiotics use grows for gut health, VSL#3 has designations for specific GI issues 3
... Loading Buffer contains a precipitant to ensure that ... tracking dye to allow the user to follow ... ReddyRun™: ABgene ® s proprietary mixture ... same buffer composition used in ReddyRun™ molecular weight ...
... Insulin exerts its ... the insulin receptor, a ... of two Alpha subunits ... arranged in the following ...
... Gel loading buffer is especially formulated ... of nucleic acids. The gel loading solution ... sucrose to add density and facilitate sample ... nucleases that require divalent cations and SDS ...
... solution, Type I is ... and agarose gel electrophoresis ... offers the advantage of ... blue and xylene cyanole). ...
Biology Products: